Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dothiepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | MC3R | P41968 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dothiepin SCHEMBL684145 | 1.00 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL3374653 | 1.00 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL34483 | 1.00 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL29369112 | 1.00 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL35427 | 0.99 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL35428 | 0.99 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL29400117 | 0.99 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL35426 | 0.99 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL3409482 | 0.99 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 | |
| Dothiepin SCHEMBL15795798 | 0.89 | HTR2B (0.80) | HRH1ALDH1A1SLC6A2KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6954 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4706649-A1 | USE OF ADRENALIN FOR THE TREATMENT OF SHOCKS | BIOPROJET (FR) | 2026-03-11 | — | — | EP | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-12496300-B2 | Methods of treating acute depression and anxiety | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-0736045-B1 | USE OF MONO-3,6-ANHYDRO-CYCLODEXTRINS FOR SOLUBILISING A HYDROPHOBIC COMPOUND AND MONITORING THE PURITY OF AN ENANTIOMER, AND METHOD FOR PREPARING SAID CYCLODEXTRINS | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1999-03-17 | — | — | EP | claimed |
| US-5760016-A | Use of mono-3,6-anhydrocyclodextrins for solubilizing a hydrophobic compound and for controlling the purity of an enantiomer and process for the preparation of these cyclodextrins | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1998-06-02 | — | — | US | claimed |
| EP-0835660-A1 | Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions | Merckx, Gaston Edmond Filomena (BE) | 1998-04-15 | — | — | EP | claimed |
| CN-1173330-A | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitiors | AKZO NOBEL NV (NL) | 1998-02-18 | — | — | CN | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0610351-A1 | NEW DRUG FORMULATIONS WITH ION-EXCHANGERS | Pharmacia & Upjohn Aktiebolag (SE) | 1994-08-17 | — | — | EP | claimed |
| US-5256409-A | Complexing two drug haptens to carrier protein | THERAPEUTIC ANTIBODIES, INC. (US) | 1993-10-26 | — | — | US | claimed |
| WO-1993007860-A1 | NEW DRUG FORMULATIONS WITH ION-EXCHANGERS | KABI PHARMACIA AB (SE) | 1993-04-29 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0089948-B1 | PHARMACEUTICAL COMPOSITIONS | COPPEN, Alec James (GB) | 1985-08-14 | — | — | EP | claimed |